{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:44:36Z","timestamp":1793969076764,"version":"4.8.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009253","name":"European Association for the Study of the Liver","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016338","name":"Imperial Experimental Cancer Medicine Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["2023R1A2C2004339"],"award-info":[{"award-number":["2023R1A2C2004339"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["RCCPDB-Nov21\/100008"],"award-info":[{"award-number":["RCCPDB-Nov21\/100008"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006662","name":"National Institute on Handicapped Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023178","name":"Cancer Treatment and Research Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023178","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jhepr.2025.101595","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:23:41Z","timestamp":1758709421000},"page":"101595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study"],"prefix":"10.1016","volume":"7","author":[{"given":"Pasquale","family":"Lombardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1132-5217","authenticated-orcid":false,"given":"Jung Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2399-5376","authenticated-orcid":false,"given":"Giulia F.","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Celsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia A.M.","family":"Fulgenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9164-3671","authenticated-orcid":false,"given":"Antonio","family":"D\u2019Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Stefanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4048-114X","authenticated-orcid":false,"given":"Niraj C.","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4646-1438","authenticated-orcid":false,"given":"Emily","family":"Warmington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5903-8191","authenticated-orcid":false,"given":"Thomas U.","family":"Marron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7260-532X","authenticated-orcid":false,"given":"Matthias","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Scheiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beodeul","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Yeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0738-417X","authenticated-orcid":false,"given":"Wei-Fan","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Wietharn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6189-0578","authenticated-orcid":false,"given":"Marianna","family":"Silletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4629-7762","authenticated-orcid":false,"given":"Alessandro","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3007-3190","authenticated-orcid":false,"given":"Chun-Yen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0402-4176","authenticated-orcid":false,"given":"Andrea","family":"Dalbeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-8989","authenticated-orcid":false,"given":"Gianluca","family":"Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1010-0975","authenticated-orcid":false,"given":"Martin","family":"Sch\u00f6nlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2839-5174","authenticated-orcid":false,"given":"Johann","family":"von Felden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-1845","authenticated-orcid":false,"given":"Fabio","family":"Piscaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8294-0992","authenticated-orcid":false,"given":"Peter R.","family":"Galle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4102-3474","authenticated-orcid":false,"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Pressiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-3615","authenticated-orcid":false,"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9740-0155","authenticated-orcid":false,"given":"Mario","family":"Pirisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0946-3859","authenticated-orcid":false,"given":"Giuseppe","family":"Cabibbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6979-5812","authenticated-orcid":false,"given":"Hong Jae","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3529-0103","authenticated-orcid":false,"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2025.101595_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jhepr.2025.101595_bib2","article-title":"Systemic management of advanced HCC: an increasingly complex game","volume":"7","author":"Martirena","year":"2025","journal-title":"ESMO Gastrointest Oncol"},{"key":"10.1016\/j.jhepr.2025.101595_bib3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2025.101595_bib4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"4","author":"Rimassa","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101595_bib5","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101595_bib6","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/apt.17441","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: results from a German real-world cohort","volume":"57","author":"Jost-Brinkmann","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2025.101595_bib7","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101595_bib8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ejca.2022.08.024","article-title":"Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: results of the AB-real study","volume":"175","author":"Fulgenzi","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhepr.2025.101595_bib9","article-title":"Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab\/bevacizumab","volume":"7","author":"Wu","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2025.101595_bib10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double blinded placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2025.101595_bib11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101595_bib12","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double blinded placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2025.101595_bib13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jhep.2024.03.033","article-title":"Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment","volume":"81","author":"Chan","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101595_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.10.149","article-title":"LBA1 Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab (KCSG HB23-04)","volume":"35","author":"Yoo","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2025.101595_bib15","doi-asserted-by":"crossref","DOI":"10.1159\/000543666","article-title":"Multicenter phase 2 trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on atezolizumab plus bevacizumab","author":"Cheon","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2025.101595_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15235532","article-title":"Real-world systemic treatment patterns after atezolizumab and bevacizumab in patients with hepatocellular carcinoma in the United States","volume":"15","author":"Singal","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhepr.2025.101595_bib17","first-page":"127","article-title":"Real-world study of systemic treatment after first-line atezolizumab plus bevacizumab for hepatocellular carcinoma in Asia-Pacific countries","author":"Lee","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2025.101595_bib18","first-page":"1","article-title":"Lenvatinib versus sorafenib second-line therapy in patients with hepatocellular carcinoma progressed to atezolizumab plus bevacizumab: a retrospective real-world study","author":"Persano","year":"2024","journal-title":"Oncology"},{"key":"10.1016\/j.jhepr.2025.101595_bib19","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.jhepr.2025.101595_bib20","article-title":"Evaluating sorafenib (SORA-2) as second-line treatment for unresectable hepatocellular carcinoma: a European retrospective multicenter study","volume":"17","author":"M\u00f6hring","year":"2025","journal-title":"Cancers [Internet]"},{"key":"10.1016\/j.jhepr.2025.101595_bib21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-024-01647-1","article-title":"Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives","volume":"17","author":"Chen","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jhepr.2025.101595_bib22","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2025.101595_bib23","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101595_bib24","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101595_bib25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101595_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005920","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy","volume":"11","author":"Rizvi","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhepr.2025.101595_bib27","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhepr.2025.101595_bib28","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000513486","article-title":"Atezolizumab plus bevacizumab versus sorafenib in the Chinese subpopulation with unresectable hepatocellular carcinoma: phase 3 randomized, open-label IMbrave150 study","volume":"10","author":"Qin","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2025.101595_bib29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2025.101595_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double blinded phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2025.101595_bib31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3350\/cmh.2023.0553","article-title":"Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab\/bevacizumab failure: a real-world study","volume":"30","author":"Chon","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101595_bib32","unstructured":"Pressiani T, Boni C, Rimassa L, et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis."},{"key":"10.1016\/j.jhepr.2025.101595_bib33","unstructured":"Marrero JA, Kudo M, Venook AP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study."},{"key":"10.1016\/j.jhepr.2025.101595_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221097934","article-title":"Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis","volume":"14","author":"Bang","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jhepr.2025.101595_bib35","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1111\/liv.14496","article-title":"Regorafenib in previously treated advanced hepatocellular carcinoma: impact of prior immunotherapy and adverse events","volume":"40","author":"Yoo","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101595_bib36","doi-asserted-by":"crossref","first-page":"S1535","DOI":"10.1016\/j.annonc.2023.10.291","article-title":"156P Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial","volume":"34","author":"Cheon","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2025.101595_bib37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000520278","article-title":"First-line immune checkpoint inhibitor-based sequential therapies for advanced hepatocellular carcinoma: rationale for future trials","volume":"11","author":"Cabibbo","year":"2022","journal-title":"Liver Cancer"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925002770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925002770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:48:09Z","timestamp":1773323289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555925002770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2589555925002770"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101595","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101595","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101595"}}